![]() |
Name |
2,3,4-Trimethylhexane
|
Molecular Formula | C9H20 | |
IUPAC Name* |
2,3,4-trimethylhexane
|
|
SMILES |
CCC(C)C(C)C(C)C
|
|
InChI |
InChI=1S/C9H20/c1-6-8(4)9(5)7(2)3/h7-9H,6H2,1-5H3
|
|
InChIKey |
RUTNOQHQISEBGT-UHFFFAOYSA-N
|
|
Synonyms |
2,3,4-TRIMETHYLHEXANE; 921-47-1; Hexane, 2,3,4-trimethyl-; 2,3,4-trimethyl-hexane; EINECS 213-066-2; DTXSID50870795; AKOS006242755; FT-0763841; Q5651190
|
|
CAS | 921-47-1 | |
PubChem CID | 13533 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 128.25 | ALogp: | 4.2 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 9 | QED Weighted: | 0.537 |
Caco-2 Permeability: | -4.25 | MDCK Permeability: | 0.00001370 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.863 |
30% Bioavailability (F30%): | 0.891 |
Blood-Brain-Barrier Penetration (BBB): | 0.844 | Plasma Protein Binding (PPB): | 94.17% |
Volume Distribution (VD): | 1.977 | Fu: | 4.98% |
CYP1A2-inhibitor: | 0.765 | CYP1A2-substrate: | 0.74 |
CYP2C19-inhibitor: | 0.102 | CYP2C19-substrate: | 0.947 |
CYP2C9-inhibitor: | 0.494 | CYP2C9-substrate: | 0.187 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.137 |
CYP3A4-inhibitor: | 0.187 | CYP3A4-substrate: | 0.536 |
Clearance (CL): | 12.808 | Half-life (T1/2): | 0.262 |
hERG Blockers: | 0.011 | Human Hepatotoxicity (H-HT): | 0.026 |
Drug-inuced Liver Injury (DILI): | 0.109 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.05 | Maximum Recommended Daily Dose: | 0.03 |
Skin Sensitization: | 0.044 | Carcinogencity: | 0.056 |
Eye Corrosion: | 0.96 | Eye Irritation: | 0.993 |
Respiratory Toxicity: | 0.06 |